���发背景与监管地位 — What the Evidence Shows

By Editorial Desk · published 2026-07-31 · last reviewed 2026-08-01 · News

The short version of heptapeptide fits in a sentence. The long version — which is the one that helps — is below.

This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.

研发背景与监管地位

Semax 是人工设计的七肽，序列为 Met-Glu-His-Phe-Pro-Gly-Pro，骨架取自促肾上腺皮质激素片段 ACTH(4-10)。它于二十世纪八十年代在苏联的分子遗传学研究机构内合成。设计目标是保留该片段与注意力和记忆相关的活性，同时剔除促皮质激素释放等内分泌作用。此后俄罗斯将其登记为药品并进入临床使用。

当时的短肽研究普遍关注能否穿越血脑屏障、在低剂量下产生中枢效应，Semax 属于这一路线。鼻内给药是其主要使用方式，俄语文献报道的适应症涵盖缺血性卒中、短暂性脑缺血发作、认知功能减退以及视神经病变。这些研究大多发表在当地期刊上，样本规模与终点设置同西方试验惯例存在差异，国际同行对其临床证据的强度看法不一。

Semax Background And Mechanism

Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It was derived from the ACTH(4-10) fragment, a short segment of adrenocorticotropic hormone that lacks the hormonal activity associated with the full-length peptide. Researchers at the Institute of Molecular Genetics in Moscow developed the compound during the 1980s. It has been registered as a pharmaceutical product in Russia and several neighbouring countries, where it is supplied as a nasal solution, and it is also sold internationally as a research chemical.

The proposed mechanism centres on neurotrophic signalling rather than direct receptor activation. Semax is reported to increase expression of brain-derived neurotrophic factor and nerve growth factor in several brain regions, and to shift the balance between excitatory and inhibitory neurotransmitter systems. Interaction with melanocortin receptors has been suggested because of the parent ACTH fragment. Many of these findings come from rodent studies, and the extent to which they translate to human physiology remains an open question.

Scientific literature on semax is unevenly distributed. A substantial share of published work originates from a small number of laboratories in Russia, while independent replication elsewhere is limited. Human data consist mostly of small trials with short follow-up, and several reported outcomes rely on subjective rating scales. Questions about how much intact peptide reaches the central nervous system after nasal administration, and how long it persists there, are still unresolved. The compound is best described as an active research subject rather than a settled pharmacological agent.

Semax at a glance

Semax Structure and Research Background

Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Its chain combines the first seven residues of corticotropin with a C-terminal proline-glycine-proline extension, a modification intended to slow enzymatic breakdown. The free peptide has a molecular mass near 813.9 daltons. It belongs to the class of ACTH-derived fragments studied for central nervous system activity rather than for adrenal steroid stimulation. This structural relationship to a natural hormone fragment is the usual starting point for describing the compound in the literature.

Development took place during the 1980s at institutes of the Russian Academy of Sciences, where peptide fragments of ACTH were screened for cognitive and neuroprotective effects. The compound received regulatory approval in Russia as a nasal preparation, marketed for conditions such as ischemic stroke, transient ischemic attacks, and optic nerve disorders. Registration in other countries has not followed. Most published clinical reports originate from a small number of Russian research groups, and independent replication outside that setting remains limited. The regulatory status therefore differs sharply between Russia and the rest of the world.

Related pages on this site

• Practical review
• Efficient trends
• Tracked reference
• Tracked reference
• Adaptive toolkit
• Gradual workbook
• Adaptive index
• Smart digest

Semax Origin and Molecular Structure

Pharmacological accounts link semax to melanocortin signalling and to modulation of neurotrophic factor expression, particularly brain-derived neurotrophic factor and nerve growth factor. Much of this evidence comes from rodent studies using intranasal delivery, a route chosen because it allows peptides to reach the central nervous system with limited systemic exposure. Whether the same mechanisms operate in humans at comparable magnitude remains an open question. The precise receptor or receptors responsible for the reported behavioural and neuroprotective effects have not been conclusively identified.

Clinical reports describe use in ischaemic stroke, transient ischaemic attack, optic nerve conditions, and cognitive complaints, but most of these studies are small and were conducted in a single region. Systematic reviews have generally described the evidence base as limited in size and variable in methodological quality. Randomised controlled data suitable for international regulatory assessment are scarce. As a result, major treatment guidelines outside Russia do not include the peptide, and interest in it remains largely research-driven rather than routine clinical.

Semax Background and Molecular Structure

Semax is a synthetic heptapeptide whose sequence is Met-Glu-His-Phe-Pro-Gly-Pro. It was developed as a fragment analog of adrenocorticotropic hormone, modeled specifically on the ACTH(4-10) region. The first four residues reproduce that fragment, while a Pro-Gly-Pro tripeptide is appended at the C-terminus. Work on the compound originated in Russia, where it entered clinical use as an intranasal preparation. Its sequence places it among short regulatory peptides studied for effects on the central nervous system rather than on the adrenal axis.

The C-terminal Pro-Gly-Pro extension is not incidental. Proline-rich tails are known to resist several common peptidases, and the published literature attributes the longer half-life of Semax, relative to unmodified ACTH fragments, to this feature. The modification also removes the melanocyte-stimulating and corticosteroidogenic activity that characterizes longer ACTH-derived sequences. Because the molecule is small and hydrophilic, it is typically formulated as an aqueous solution for intranasal or parenteral delivery. Acetylation or amidation at the termini appears in closely related research peptides and shifts the mass by a fixed increment.

Chemical Identity and Research Background

Development of the compound took place in the Soviet Union during the 1980s, largely through peptide research groups affiliated with the Shemyakin-Ovchinnikov Institute and Moscow State University. Investigators screened fragments of adrenocorticotropic hormone for activity on the central nervous system while attempting to separate cognitive effects from hormonal ones. The shortened sequence was selected because it retained behavioral activity in animal models without stimulating corticosteroid release. Early publications described the molecule as an ACTH(4-10) analog.

Published research on this peptide originates mainly from Russian laboratories, and the wider international literature is comparatively thin. Studies have used rodent models of stroke, hypoxia, and memory tasks, with a smaller number of human trials reported. Reported outcomes include changes in attention and memory measures, along with effects on neurotrophic factor expression in some experiments. Small sample sizes, inconsistent dosing protocols, and limited independent replication are widely noted limitations, so the strength of the clinical evidence remains an open question.

Background from the literature

=== Tertiary structure === GALE structure has been resolved for a number of species, including E. coli and humans. GALE exists as a homodimer in various species. While subunit size varies from 68 amino acids (Enterococcus faecalis) to 564 amino acids (Rhodococcus jostii), a majority of GALE subunits cluster near 330 amino acids in length. Each subunit contains two distinct domains. An N-terminal domain contains a 7-stranded parallel β-pleated sheet flanked by α-helices. Paired Rossmann folds within this domain allow GALE to tightly bind one NAD+ cofactor per subunit. A 6-stranded β-sheet and 5 α-helices comprise GALE's C-terminal domain. C-terminal residues bind UDP, such that the subunit is responsible for correctly positioning UDP-glucose or UDP-galactose for catalysis.

This type of filtration is typically selected for feeds containing a high proportion of small particle size solids (where the permeate is of most value) because solid material can quickly block (blind) the filter surface with dead-end filtration. Industrial examples of this include the extraction of soluble antibiotics from fermentation liquors. The main driving force of cross-flow filtration process is transmembrane pressure. Transmembrane pressure is a measure of pressure difference between two sides of the membrane. During the process, the transmembrane pressure might decrease due to an increase of permeate viscosity, therefore filtration efficiency decreases and can be time-consuming for large-scale processes. This can be prevented by diluting permeate or increasing flow rate of the system.

According to the Endocrine Society, there is "growing evidence suggesting that obesity is a disorder of the energy homeostasis system, rather than simply arising from the passive accumulation of excess weight" and that "obesity pathogenesis involves two related but distinct processes: (1) sustained positive energy balance (energy [caloric] intake > energy expenditure) and (2) resetting of the body weight "set point" at an increased value." In other words, the fundamental cause of obesity is consuming more calories than are used by the body, and the body adapting to a heavier weight as the standard for the individual.

Sources: en.wikipedia.org

Further detail

Disinfecting uses a chemical product, which is a process that kills the germs on the surfaces. In most situations, regular cleaning of surfaces with soap and detergent, not necessarily disinfecting those surfaces, is enough to reduce the risk of COVID-19 spread. Disinfection is only recommended in indoor settings — schools and homes — where there has been a suspected or confirmed case of COVID-19 within the last 24 hours. In most situations, regular cleaning of surfaces with soap and detergent, not necessarily disinfecting those surfaces, is enough to reduce the risk of COVID-19 spread." The CDC issued a special report "Knowledge and Practices Regarding Safe Household Cleaning and Disinfection for COVID-19 Prevention" due to the increased number of calls to poison centers regarding exposures to cleaners and disinfectants since the onset of the COVID-19 pandemic, concluding that "Public messaging should continue to emphasize evidence-based, safe cleaning and disinfection practices to prevent SARS-CoV-2 transmission in households, including hand hygiene and cleaning and disinfection of high-touch surfaces." CDC provides a Guideline for Disinfection and Sterilization in Healthcare Facilities.

The ruling does allow for team uniforms to display "Russia" on the uniform as well as the use of the Russian flag's colors within the uniform's design, although the name should be up to equal predominance as the "Neutral Athlete/Team" designation. Russia can appeal the decision. On 19 February 2021, it was announced that Russia would compete under the acronym "ROC", after the name of the Russian Olympic Committee. On aftermatch, the IOC announced that the Russian national flag would be substituted by the flag of the Russian Olympic Committee. It would also be allowed to use team uniforms bearing the words "Russian Olympic Committee", or the acronym "ROC" would be added. On 15 April 2021, the uniforms for the Russian Olympic Committee athletes were unveiled, featuring the colours of the Russian flag. On 22 April 2021, the replacement for Russia's anthem was approved by the IOC, after an earlier choice of the patriotic Russian war song "Katyusha" was rejected. A fragment of Pyotr Tchaikovsky's Piano Concerto No. 1 is used.

== Background == During the Busan Summit on October 30, 2025, US president Donald Trump invited Chinese leader Xi Jinping to visit the United States at an appropriate time. During his May 2026 state visit to China, Trump invited Xi to the White House in September. On July 23, Trump said that Xi would be visiting on 24 September. On September 4, Reuters reported that Xi would be travelling with a large business delegation. However, The Wall Street Journal reported on September 22 that Xi was unlikely to bring a business delegation. This was Xi's first visit to the White House after 11 years. The state dinner was also the second one held during the second Trump administration, following the one held for King Charles III during his state visit in April 2026. On September 20, 2026, Chinese vice premier He Lifeng met with US secretary of treasury Scott Bessent and Trade Representative Jamieson Greer in New York City, where they agreed to set up an AI dialogue. On September 21, the Chinese foreign ministry announced that Xi would pay a state visit ‌to the US from September 23 to 25. The ministry spokesperson Guo Jiakun said that two heads of state's reciprocal visits within a six-month period are "of historic, milestone significance". On September 23, Chinese ambassador to the US Xie Feng wrote an article in the People's Daily, saying China and the US should manage their differences in good faith, and that the US should stop fabricating pretexts such as national security, economic imbalances and forced labor in trying to constrain China.

Sources: en.wikipedia.org

Frequently asked questions